A Clinical Study of GC012F Injection in the Treatment of Relapsed/Refractory BCMA + Multiple Myeloma
| Title | A Clinical Study of GC012F Injection in the Treatment of Relapsed/Refractory BCMA + Multiple Myeloma |
|---|---|
| Description | This is a single-arm, multicenter, open-label clinical study to evaluate the efficacy and safety of GC012F in patients with relapsed/refractory BCMA + multiple myeloma (MM).It is planned that 15 patients will be enrolled in this trial and treated at the optimal dose obtained in the previous trial. The trial will be divided into six phases: screening phase, leukapheresis day, baseline phase, chemotherapy pretreatment phase, cell infusion phase, and follow-up phase. After screening and at 3-5 days before GC012F infusion, for eligible patients, the investigator will decide whether they will receive chemotherapy pretreatment and choose the chemotherapy regimen according to their conditions. |
| Organism | Homo sapiens |
| Data Type | Other Type of Proteomic Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA023071 |
| Release Date | 2024-01-23 |
| Submitter | mingyue xiang (mingyue.xiang@gracellbio.com) |
| Organization | Gracell Biotechnologies Inc |
| Submission Date | 2024-01-22 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005725-01 | RRMM-IIT | 1 | Other Type of Proteomic Data | 77.7 KB | xlsx | 0 | Controlled |